🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Echo IQ Limited (ASX:EIQ)
Australia flag Australia · Delayed Price · Currency is AUD
0.3250
+0.0500 (18.18%)
Nov 20, 2026, 4:11 PM AEDT
← View all transcripts

Bell Potter Healthcare Conference

Nov 17, 2026

Summary

EchoSolve-AS is FDA-cleared and gaining U.S. use, with ~37,000 studies processed YTD and pilot sites moving toward paid contracts. Heart-failure FDA review remains active, while AUD 108m in cash funds U.S. execution.

Speaker 1

Welcome back. I'm joined now by the CEO of Echo IQ, Dustin Haines, and CFO Matthew Dodds. Welcome, gentlemen, and thank you for joining us this morning.

Dustin Haines
CEO, Echo IQ

Thanks, John. It's good to see you.

Matthew Dodds
CFO, Echo IQ

Thanks for having us.

Speaker 1

Great. Thank you. Echo IQ is a medical technology company that has developed two algorithms to assist clinicians in the diagnosis of potentially life-threatening cardiology conditions. The first of these is EchoSolve aortic stenosis for the diagnosis of, not surprisingly, aortic stenosis, being a condition which affects the efficient operation of the aortic valve. There are more than 70,000 aortic stenosis interventions in the U.S. every year, and the problem is thought to be vastly underdiagnosed. The algorithm recently received FDA approval and is now being used in the U.S.. The second algorithm is for the diagnosis of heart failure, and that too has gained recognition amongst leading institutions in the U.S., albeit is still undergoing review by the FDA. Earlier this year, the company completed a AUD 100 million funding round, and that was used to fund the commercialization activities of both these programs.

Here to tell us more about it, welcome again to Dustin. Thanks for joining us, Dustin.

Dustin Haines
CEO, Echo IQ

Great. Thanks, John, and I appreciate you guys taking the time. Sorry I couldn't be there with you guys live, but hopefully you guys can appreciate Matt and I spending our time in the U.S. making sure that we can get the business off to continued momentum with aortic stenosis, and obviously we're working with the FDA on heart failure. Look, we'll take about 20 minutes or so. We'll take about 15 minutes to present, and hopefully we'll have time for some questions. I do want to start on this slide, just letting everybody know there's nothing new that we're presenting here today that hasn't been out in the public domain. Everything you're seeing in here is either part of the quarterly or was most recently in any of the press releases we had out.

We'll make sure that this is consistent with all the news that's in the public domain today. I thank and appreciate everybody for coming. We're going to go through a couple things, and obviously we've got some disclaimers here. One of the things I wanted to just ground everybody on, and John did a nice job of explaining a little bit about what we're doing, but I think what's most important about what we do as a company, and if you've been along the story for a while, thank you very much. Bear with us for a second as I go through it. If you're new to the story, I promise you I'm going to go pretty quick on this in terms of what we do.

Obviously, it's really complex what we do, but in simplest terms, what we do is we have an AI software solution that helps doctors to diagnose cardiovascular disease better and more accurately than they do today. That's as simple as it is. What sits behind that is an incredibly complex mixture density neural network that uses the modality of echocardiograms. If you've ever been to a cardiologist, more than likely you've probably gotten an echocardiogram, which means you probably also have a few gray hairs like I do on my head. If you've gone, you've had an echo. It's a pretty simple ultrasound machine. You can see some of the pictures there in black and white.

But what we've been able to do is use the largest dataset in the world, which we have exclusive access to, which is the National Echo Database of Australia, to be able to create a model that helps the physician to identify subtle changes happening within the patient's heart to be able to determine whether or not there's presence of a disease. In many cases, the way that we're able to do that is with a high degree of sensitivity and specificity using our model, but most importantly, we can do it in real time for the clinician to provide them that extra piece of information to help them make a better diagnosis. As John said, many of the diseases we're looking at today are vastly mis or underdiagnosed. Unfortunately for cardiovascular disease, the outcomes for undiagnosed disease are pretty catastrophic.

We know that this is one of the highest mortality rates of any disease in the world today, which is still the same we see around the world. So that's what we do. We're going to get a little bit more into that in a minute as we go to a couple more slides, but I thought it was just a nice way to ground everybody on this kind of area about what we focus on today. So a couple new announcements that we have made, and I think it's important for the folks on the call to meet Matt. Matt's going to be speaking here in a few minutes, so I'll turn the reins over to him in a minute or two.

Matt just joined us as part of our management team, so as you guys can all appreciate, one of the things that makes every company successful is the depth of their management team, and Matt recently joined the organization with an incredible pedigree behind him. Obviously, he's worked with a number of multinational companies in the U.S. and around, but most importantly, Matt comes with a tremendous understanding of the U.S. market. Matt served, which as many of you will appreciate, probably in John's seats and others, as an analyst and understands Wall Street and the desire and the needs for what we do from a financial perspective. So Matt brings a host of experience there, and that really rounds out the maturity of our business.

But I think if you were just paying attention yesterday, we did just make a recent announcement yesterday of our new Chief Medical Officer who will be joining the business in January, Dr. Vasanth Nambudiri, who is coming to us with a tremendous pedigree and a background in cardiovascular disease, as well as working previously at the FDA, and having a triple board certified cardiologist on the team only strengthens our management team. So we're really excited about bringing in some of the best talent we can find in the industry to round out our management team. And what I think, which is usually a measure of a company, is not necessarily just their management team, but who's surrounding that team.

For us, it's our clinical advisors that really brings me the highest level degree of confidence in the fact that not only do we have the right technology, but we are doing the right things in the right space. Our clinical advisor team is strong. It's always been strong. We've talked a lot about Dr. Philippe Genereux and Dr. Jordy Strom as being some of our key clinical advisors in the U.S.. Dr. Genereux himself alone is the number one valve implant surgeon in the United States today. Dr. Jordy Strom is one of the top echocardiogram physicians in the U.S. out of Harvard and Beth Israel. But we just added Dr. Vinod Thourani. You can see his picture down there in the bottom. Again, this is strength on strength for us from a clinical advisor perspective.

Dr. Vinod Thourani is one of the top heart transplant surgeons in the United States today, and he is just barely number two behind Dr. Philippe Genereux in terms of valve implants that he's put in over the last several years. Again, this is just continuing to bring strength on strength. If you see our management team and you can see the level of maturity and the level of experience we have, I think seeing who is also circling themselves around the business as part of our advisors is a really key understanding of the strength that this company continues to possess as we move forward. I think the final thing that rounds out the strength of our organization is your board.

We've really been interested in building a board that can represent the growth of the business as well as the maturity of the business going forward. Most recently, we announced Mr. Scott Wilken has joined as Non-Executive Director. Scott comes to us from UBS, where he was co-head of global equities at UBS, managing about AUD 30 billion under his management. Scott brings, again, I think that nice piece that rounds out with Matt around what the U.S. markets look like, what Wall Street looks like, obviously what the ASX looks like, and also how we go forward with our business to make sure we've got that level of financial maturity. Scott just recently joined on the board, and I'm very happy to know that we're continuing to build that maturity at the highest corporate level within the organization.

Why are we so excited about where we are? I know many of you who have followed this story probably want to talk a little bit about where we're at today with the FDA, and we will get to that from a heart failure perspective. But I think it's important for us to come back to the roots of where the company was. As a company, we've been very confident in the fact that we are the nexus of cardiovascular care. When you think about echocardiograms in general, there's about 25 million echocardiogram studies being done in the U.S. alone. That number is significant because it is the first step into getting your first cardiovascular diagnosis for a disease. There's a number of things that sit at the top of that funnel when you look at it.

Things like ECGs are out there, and obviously there's a ton of those. Those are screening tools that happen oftentimes within the general practice and maybe family practice settings, maybe even in emergency room settings. Then you have the wearables, and obviously that's a really exciting and growing area. Any of you that are wearing an Apple Watch, or maybe you got a Whoop, or you even got your Oura Ring, all of those are devices that help to give some screening, at least give you some early indicators. But before you actually get that first diagnosis, more than likely you're going to get an echocardiogram done, and that is the nexus and the funnel that feeds out through the cardiovascular cascade, ultimately leading into things like CT scans and MRs and everything else.

We're really excited about the fact that we sit in the nexus of that cardiovascular disease. We interact with those physicians at the most critical time, which is that first initial diagnosis for patients, and it happens to be a very large size of that market. In fact, when you look at a heat map in the U.S., and this was just recently done, Dr. Jordy Strom presented this data most recently, you can see in the upper left corner the number of echocardiograms being done as a diagnostic imaging tool comparative to things like CT and MRI and PET scans. What you see there is that really an individual American today is about 16 mi away at minimum from an echocardiogram. That tells you how ubiquitous this test is.

When we're thinking about affecting change in a disease state that has a high mortality rate like cardiovascular disease, what you want is to be able to be at the very front point of that diagnostic odyssey for that patient to make sure they're getting their disease diagnosed correctly the first time. And we can do that very effectively by reaching that modality. What does that mean in terms of overall addressable market? For us, it's about a AUD 4 billion market when you combine the aortic stenosis market that currently is available to us today with the EchoSolve-AS, which is in the market and FDA cleared. We've been talking a lot about our heart failure model, which is the EchoSolve Heart Failure.

That's still being reviewed with the FDA, but when that clearance comes, that'll open up that full AUD 4 billion total addressable market for us. Not only do we have a tremendous number of echocardiograms available for us, you can see how large this market is and why this really gets us excited about the long-term growth opportunities for the business and beyond. Really the question is, how do we do this? Well, it's really interesting and unique in the way that we've approached this. This screen here on the right side, you're going to see a number of images. But if you see the number of images here, this is a standard echo. This is a standard ultrasound images that the physician looks at.

Well, what happens here is that the physician's going to be looking through these images, and they're going to be trying to make a diagnosis of a disease. At the same time, they're going to be looking at a number of measurements and metrics to help them paint that picture. When you look at the screen now at these images, what you're actually going to see is a number of dots show up on these images. Well, each one of those represents raw data. That's a measurement or that's a metric that also aids that physician in making that ultimate diagnosis.

Well, what we've been able to do through our mixture density neural network is we're able to take all of those measurements that you see here on the screen in those orange dots and pull them into the network, which ultimately creates a 3D version of that patient's heart. Now, through that network and through that three-dimensional version of that patient's heart, what the model can do now is look for subtle changes happening. This is where our sensitivity and specificity, now those are two kind of AI diagnostic terms, but ultimately what it means is how good are you, how accurate are you.

We're able to take all that information, because we're looking at this now from the measurements and the metrics perspective, we can get a very high level of sensitivity and specificity to find those subtle changes happening and be able to help that physician make that diagnosis. An example of that, as we talk about things like aortic stenosis, about 15%-20% of patients who have the disease are mis or underdiagnosed. Imagine this disease, aortic stenosis by itself, has a mortality rate of 50% at two years. If you can imagine a patient who gets mis or underdiagnosed at that critical moment in time, if they get sent home, there's a good chance that two years from now, they may not make it back to the clinic because their mortality rate is high.

It's so critical we get this patient diagnosed accurately upfront, accurately on time, and ultimately get them into the next level of clinical care. That's why these AI tools are so important and why we have been able to develop a tool that has the highest degree of sensitivity and specificity that meets the needs of where those customers are today. What does that mean in terms of our output? It's quite simple. We actually work off a probability score, so we're able to give to the physician in real time the probability of that patient having that disease or underlying disease. We give it to them in a traffic light symbol. It's either red, yellow, or green.

What that means is when we have that high degree of probability that that patient has aortic stenosis, we are very confident that they have underlying severe aortic stenosis. What's interesting is we get to this medium probability, it starts to get into this area that we're going to talk about in a minute around early intervention, and what does that mean to intervene early? When somebody has a mild form of a disease, but you know that disease is going to progress, when can we intervene and when does it make sense to intervene to make sure that they're getting the best possible outcomes? We have that red and that yellow to give that physician that clear confidence about where they are in terms of their progressing of disease.

Then, of course, on the green, we actually can be able to demonstrate to the physician, we can screen the patient out. That's what makes a physician more happy than telling a patient: Good news, I'm pretty confident you do not have this disease, and that patient maybe can go on to other areas to get diagnosed for, but we can be confident in screening those patients out. Why are we so comfortable and confident about this? Well, because we've been able to train the model on one of the largest datasets in the world, and because we have exclusive access to that dataset for commercializing technology, what that means is we can overlay things like mortality to give our confidence even higher in terms of what the sensitivity and specificity is for our model.

When we show a physician these outputs, we can say: We know with a high degree of certainty that this patient has underlying disease, and we can show you the mortality curves that demonstrate why that sensitivity or specificity is so high for that patient, which gives that physician that next layer of confidence knowing that when they're using the tool, we can find those patients that oftentimes get missed or underdiagnosed, or in some cases, aren't getting diagnosed at all because they're not getting into the right level of care. So what does that mean in terms of what we've done so far? We've been able to recently do some institutional news. You guys have probably heard about the Mount Sinai commercial agreement that happened a few months ago. This is one of the top five nationally ranked hospitals in the U.S. today.

It's in Midtown New York. We're going through our commercial agreement with them now. We're fully installed and up and running within Mount Sinai. Many of you have seen the Mayo Clinic. Most people know who Mayo Clinic is around the world. We've got a three-year commercial agreement with Mayo Clinic for the heart failure solution, so obviously they've looked to try to bring this in even before we've gotten FDA clearance. Once we get the FDA clearance, we will be working with Mayo to integrate in for EchoSolve heart failure. We also just announced our cardio-oncology study with the Mayo Clinic. This is a knock-on study looking at patients who are going through cancer treatments and those cardiotoxic events that happen from their chemotherapy and cancer treatments, and can we actually help to identify those patients which may actually have fewer or more of those side effects?

This is a really interesting study. Hopefully getting you guys some information very shortly on the outcomes from that study. Then most recently, we announced the data licensing agreement with Advara Heartcare right there in Australia. This is one of the largest private-owned cardiovascular centers in Australia today, and we have exclusive access now over the next three years over about 1 million or so patient records, which includes the echocardiograms as well as the images. This is not only going to bolster our data moat around our AI technology, but it also helps us to now look at a pipeline when we look at things like mitral valve and tricuspid valve regurgitation, which Matt will talk about here in a few minutes.

You can see as we continue to move through the progress of the organization, we're continuing to get those commercial agreements coming across. We're shoring up our pipeline as well as our data moats to be able to make sure that we're getting the right partners within the organization. Of course, one of the things that most people talk about with us is the pathway to reimbursement and how is that going and what does that mean for a company like us? Looking at this space and you look at this sector, reimbursement matters. Whether you're looking at our peers in this sector or you're looking at other U.S. peers, reimbursement is a really major topic. We've been able to announce that we've got a heart failure code as 0932T, which is a category three code.

Most recently, CMS has been working through their most recent updates on software as a medical service. We saw the first announcement from them just recently where we saw the solidification of heart failure in that new tech APC, which allows us to have the confidence that that code's going to continue to pay very well as a reimbursement for heart failure. More importantly, what CMS signaled to us in that initial conversation for new tech APC is that aortic stenosis has a pathway now. While we were using a miscellaneous code and we had various coverage on that, moving into this new tech APC is going to allow aortic stenosis now to get a signature code that will continue to move through the modality of echocardiogram.

We see heart failure now today, and we see a path forward for aortic stenosis, and we'll be updating the market on that in due course as we continue to work with CMS. What gives me the confidence is looking at leading indicators, and I think this is something that's important for each of you as you're saying: Well, how do we track the business and where is the business going? Obviously, revenue is the ultimate litmus test for us in terms of progress and growth. As we get this leading indicator in front of us, it's number of echocardiograms that we process in any given month or any given quarter throughout the year. This was in our most recent quarterly, so if you saw the quarterly, you will see this.

Year- to- date, we have had about 37,000 echocardiogram studies that we have already processed through our U.S. sites, and that you can see the growth that you show there, whether it is quarter-on-quarter or year-on-year. What gets me more excited is if you look at September month by itself, we had about 12,345 studies. That shows that we are continuing to get that momentum and progress moving. Obviously, a big bulk of this is as the Mount Sinai deal starts to progress and the integration goes through, we are seeing those. We got the Beth Israel , integration happening and then a host of other hospitals that have come on board. This is our leading indicator. We see these come through, which shows that we are getting good pickup, good utilization of the technology.

We are processing lots of studies, and obviously this is that leading indicator as we start to build our revenue base going forward. This gives me the confidence we have that we are on the right track. Physicians are seeing the value, they are integrating this in, and they are using it throughout their clinics. I think what has been really kind of a testament to that is the strategic partnership we have with Pro Medicus. Many of you saw that recent announcement with Pro Medicus where we had the convertible note. We solved that, and we finalized that in September, and now we have moved on to the reseller agreement, and we have been working on that with their team. Sam Hupert and the team over there have been great. Obviously, it is a complex reseller agreement as we think about integrations, and we make sure the tech is going to work really well.

We talk about those revenue-sharing milestones, and both companies are committed to get this one done in due course, because it is really going to help both companies. I think it helps from a revenue perspective, both companies, but more importantly, it demonstrates that coming together through a PACS system and an AI-enabled tool, that it is going to be a uniform tool to be able to help those cardiology clinics. This has really been a great partnership. We have not obviously funded the first AUD 10 million. As John said earlier, we have already done a AUD 100 million raise earlier in the year.

A big bulk of that money is still sitting in cash available to us now, but obviously, this AUD 10 million with an initial potential AUD 10 million coming, is sitting on the wings, and we will be finalizing the reseller agreement, which then funds the convertible note, hopefully here in due course. My final couple slides, I think is important to talk about progress going forward, and no pun intended with the slide here on progress study. We have been building our clinical evidence, and you guys have heard us talk about this around how important clinical evidence is going to be to not only have the AI tool, but also to be able to show the utility of this technology. The Beth Israel real-world clinical study on aortic stenosis, we have been talking about this data coming.

We believe that the primary endpoints are going to be very good, so we're looking forward to giving you guys those results on the primary endpoints here for that study. It's a 12-month study looking at about 2,000 patients, and I can tell you the initial feel from the physicians is that this has a significant impact on their practice. Along with that, we've got the cardio-oncology study. We're going to be seeing that data readout here imminently. We'll be able to share that with the market as well. Between these two studies, we'll combine that data together. Why this is so important is outside of our control, is also what third-party evidence has been able to demonstrate in this space.

If you're a data nerd like myself and you go out there and you're watching data, and I happen to be sitting in the room when Dr. Genereux was presenting this study from the PROGRESS trial, Journal of Medicine is the most revolutionary data that we've seen in cardiovascular disease for a long time. Basically, what this data shows is that now there is clear evidence that intervening earlier for patients with aortic stenosis has demonstrated better outcomes for those patients and reduced hospital costs overall. What does that mean for a company like Echo IQ? When I showed you before, our analysis is able to demonstrate those high probabilities, but that medium probability is where we are one of the only companies right now.

In fact, I think we are the only company who can give those physicians that understanding of what's happening with those moderate patients, that moderate-severe, or severe aortic stenosis. This third-party evidence that's now being published in the New England Journal of Medicine is demonstrating the movement now in this space for aortic stenosis and that TAVR market where we're going to see patients now coming in that previously before would have been sent home and done what was watch and wait, who will now be need to be moved into an actual surgical intervention. This is really exciting clinical evidence that's building and evidence that we're generating on our own as an organization. With that, I'm going to kick it over to Matt after this slide, but I just wanted to just touch this. We'll do it in the Q&A.

What do we know about heart failure with EchoSolve Heart Failure? What's been done and what's coming? Nothing is new here. I know you guys would love for me to make an announcement today. We won't be making an announcement today, but I will tell you that we've worked with the FDA. Obviously, we've appealed the non-substantial equivalence, which we announced and we had a webinar regarding. We've also announced that we will be having our meeting with the FDA. What's coming? FDA response. That response will be imminent. We know the possible outcomes, as we had already announced the market, and we will do our best to get you guys that information as quickly as possible. But what we do know is it has no material impact on the Pro Medicus, Mayo Clinic, or Advara agreements that we have signed already today.

I know I will get it in the Q&A, but I just wanted to have a slide here to let you guys know that we are aware of it. I am hoping to have some news for you guys very shortly on that. I am going to kick it over to Matt now to walk us through the financials and what is coming.

Matthew Dodds
CFO, Echo IQ

All right. Thanks, Dustin. Just three slides to go. For the September quarter, we finished with, as I think both Dustin and John mentioned, about AUD 108 million in cash, no debt. We are very well funded to execute the U.S. plan, and that is independent of the heart failure timeline. Big move in the quarter, again, was the institutional placement of AUD 100 million. In terms of the quarterly performance, operating cash outflow was AUD 5.9 million, mostly people and corporate costs as we build out the U.S. team. On the appendix 4C calculation, that is about 18 quarters of funding at the September quarter run rate, and that is with zero revenue contribution. Investing outflows were mainly due to the Advara license, which Dustin noted, and it gives us exclusive access to between half a million and 1 million echo studies. In terms of There we go. Did I get it?

There we go. In terms of upcoming milestones, short-term priorities, turning our U.S. hospital relationships into contracted enterprise-level deployments, starting with aortic stenosis. On EchoSolve heart failure, our administrative appeal has been filed and accepted, as Dustin said. Timing and outcome sit with the FDA. Heart failure reimbursement and the larger heart failure integrations are shown as subject to clearance in the slide. In the medium term, we expect more tier one hospital system moving from pilots to contracts. The release of a large outcome study to support payer and guideline discussions, progress on the aortic stenosis and heart failure reimbursement, as Dustin noted, and a move from single sites to hospital networks. Then finally, new indications on the platform, which is my final slide. If you look at our sequencing, aortic stenosis, again, FDA cleared. It is already in use at U.S. academic and private practice sites.

Heart failure is next, again, subject to FDA clearance. As we noted, it has an established reimbursement code, and it runs on the same installs as aortic stenosis. Each new indication adds value at the sites we already serve. Then starting in 2027, cardio-oncology, we expect data from the Mayo Clinic to be announced in the coming months, followed by hypertrophic cardiomyopathy. Then a little further out, we have got pulmonary hypertension and mitral regurgitation, which are both large additional indications, and that is where the Advara data matters the most. We have been making nice progress on bringing the Advara data in-house for an analysis. At this point, John, I will turn it back to you, and happy to take some questions.

Speaker 1

Squeeze in one quick question, if I may. Dustin, 37,000-odd usages of the aortic stenosis algorithm. That is overwhelming levels of uptake. You must be very pleased with that. What is your expectation there now that that is going to convert into real-life contracting revenue over the next 12 months or so?

Dustin Haines
CEO, Echo IQ

Yeah, great question. High degree of confidence. If I had Nick Lubbers, our head of commercial, on here, I think he would tell you that his confidence level is very high. I think a lot of these were, when we originally did contracts, these were 90-day free pilots. We are getting some of the folks comfortable in using it. What we are seeing now is that that is moving now into full clinical use. We have got red lines on a number of contracts out there to move these from initial kind of pilot programs to full revenue-generating, cash-paying programs. You should see that happening very quickly.

Speaker 1

Yeah, and look, I would love to ask you some more questions about the impediments to why so many patients are missed in the initial diagnosis. Look, we will do that another time. When is your next visit to these shores, Dustin?

Dustin Haines
CEO, Echo IQ

Well, I am hoping I do it when we announce heart failure.

Speaker 1

Okay. All right then. That will be a great outcome. Thank you very much for your time. Thank you, Matthew, as well. We are going to wrap it up there. We have got a short break, and then we will be back on the other side of that. Thank you.

Matthew Dodds
CFO, Echo IQ

All right. Thank you.

Dustin Haines
CEO, Echo IQ

Thank you, guys.